Revelation Biosciences (REVB) Assets Average (2020 - 2026)
Revelation Biosciences (REVB) posted quarterly Assets Average of $12.2 million for Q4 2025, up 82.9% year-over-year from $6.7 million in Q4 2024, and up 33.9% quarter-over-quarter from $9.1 million in Q3 2025.
Revelation Biosciences (REVB) Assets Average (2020 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Assets Average for 6 consecutive years, with $12.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average rose 82.9% year-over-year to $12.2 million; the TTM figure through Dec 2025 stood at $12.2 million (up 82.9% YoY), while the FY2025 annual figure was $9.1 million, down 3.34% from the prior year.
- Assets Average grew to $12.2 million in Q4 2025 per REVB's latest filing, from $9.1 million in the prior quarter.
- Across five years, Assets Average topped out at $74.1 million in Q1 2021 and bottomed at $4.7 million in Q2 2025.
- Historically, Assets Average has averaged $20.7 million across 5 years, with a median of $12.0 million in 2023.
- Annual changes were most pronounced in 2022 — Assets Average sank 93.24% — and 2023, when it jumped 181.51%.
- Revelation Biosciences' Assets Average stood at $37.8 million in 2021, then slumped by 83.99% to $6.1 million in 2022, then jumped by 118.35% to $13.2 million in 2023, then sank by 49.45% to $6.7 million in 2024, then soared by 82.9% to $12.2 million in 2025.
- Business Quant data shows REVB's Assets Average at $12.2 million in Q4 2025, $9.1 million in Q3 2025, and $4.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | 12.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.04 Mn |
| Dec 31, 2025 | 12.22 Mn |
| Sep 30, 2025 | 9.13 Mn |
| Jun 30, 2025 | 4.68 Mn |
| Mar 31, 2025 | 5.30 Mn |
| Dec 31, 2024 | 6.68 Mn |
| Sep 30, 2024 | 9.50 Mn |
| Jun 30, 2024 | 13.49 Mn |
| Mar 31, 2024 | 13.46 Mn |
| Dec 31, 2023 | 13.22 Mn |
| Sep 30, 2023 | 15.13 Mn |
| Jun 30, 2023 | 17.08 Mn |
| Mar 31, 2023 | 11.81 Mn |
| Dec 31, 2022 | 6.05 Mn |
| Sep 30, 2022 | 5.38 Mn |
| Jun 30, 2022 | 6.07 Mn |
| Mar 31, 2022 | 5.01 Mn |
| Dec 31, 2021 | 37.80 Mn |
| Sep 30, 2021 | 73.72 Mn |
| Jun 30, 2021 | 73.96 Mn |